Precede Bio Insight debuts as a first-of-its-kind product enabling genome-wide inference of gene expression, pathway activity, and cell states ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...

Detection Market · GlobeNewswire Inc. The cell-free tumor DNA detection market is set to experience significant growth, expanding from $2.58 billion in 2025 to $3.02 billion in 2026 at a CAGR of 17.2% ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

Continued innovation of proprietary cell-free cloning technology has improved synthesis success rates, enabling pricing as low as $0.15 per base pair. SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a ...

Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA. Sintilimab plus bevacizumab, oxaliplatin, and ...

Elegen has launched ENFINIA™ IVT Ready DNA, a cell-free gene synthesis platform that provides full-length linear DNA templates encoded poly(A) tails for in vitro transcription. The templates are ...

Clonal, cell-free DNA with unmatched length, complexity and accuracy now available at industry-leading prices. Elegen today announced significant price reductions across its ENFINIA™ DNA portfolio, ...

Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...